Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$5.63 USD
-0.25 (-4.25%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $5.63 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EBS 5.63 -0.25(-4.25%)
Will EBS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EBS
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
Other News for EBS
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. ...
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential ...
Emergent BioSolutions (EBS) Explores Brincidofovir for Mpox Treatment
Emergent BioSolutions (EBS) Applauds Naloxone Accessibility in U.S. House
Emergent BioSolutions 'applauds' OTC naloxone availability in U.S. House